The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue

NCT ID: NCT01661595

Last Updated: 2018-07-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-11-30
• Study Completion Date: 2015-06-30

Brief Summary

This study is funded by the Moody Endowment. In this project, we will investigate the potential effect of skeletal muscle nitric oxide (NO) production on skeletal muscle anabolism, muscle strength, physical function, and body composition in older individuals. Further, we will determine whether augmentation of NO-mediated signaling reduces fatigue and fatigability.

Detailed Description

The Investigators hypothesize that upregulation of skeletal muscle NO-cGMP mediated responses through phosphodiesterase (PDE) inhibition by sildenafil or tadalafil causes an acute anabolic response of skeletal muscle protein synthesis. NO is well-known to elicit vasodilation through stimulation of cGMP signaling, and NO-mediated changes in muscle perfusion may influence both skeletal muscle anabolism and perceptual fatigue. To measure skeletal muscle protein synthesis, we will infuse a stable isotope tracer of phenylalanine and measure its incorporation into skeletal muscle proteins following a dose of sildenafil, tadalafil, or placebo. The Investigators will also determine whether differences exist between men and women in response to PDE inhibition. As skeletal muscle NO-cGMP signaling has been implicated in fatigue responses, we will assess the acute effect of sildenafil and tadalafil on fatigue. Fatigue can be manifested both as a performance deficit at a local level (e.g., a reduced ability of skeletal muscle to produce power or force) as well as a subjective experience of lacking physical or mental energy. Accordingly, we will use more than one means (skeletal muscle performance, fatigue questionnaires, accelerometers) to study fatigue. The Investigators hypothesize that sildenafil or tadalafil will acutely reduce exercise-associated fatigability and skeletal muscle fatigue development

Conditions

Fatigue

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Sildenafil / Placebo

50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 0-4. Placebo for weeks 5-8.

Group Type: ACTIVE_COMPARATOR

Sildenafil

Intervention Type: DRUG

50 mg/day for 4 weeks

Placebo

Intervention Type: DRUG

Placebo 1 capsule per day for four weeks.

Tadalafil / Placebo

10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 0-4. Placebo for weeks 5-8.

Group Type: ACTIVE_COMPARATOR

tadalafil

Intervention Type: DRUG

10 mg/day for 4 weeks.

Placebo

Intervention Type: DRUG

Placebo 1 capsule per day for four weeks.

Placebo / Sildenafil

Placebo for weeks 0-4. 50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 5-8.

Group Type: ACTIVE_COMPARATOR

Sildenafil

Intervention Type: DRUG

50 mg/day for 4 weeks

Placebo

Intervention Type: DRUG

Placebo 1 capsule per day for four weeks.

Placebo / Tadalafil

Placebo for weeks 0-4. 10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 5-8.

Group Type: ACTIVE_COMPARATOR

tadalafil

Intervention Type: DRUG

10 mg/day for 4 weeks.

Placebo

Intervention Type: DRUG

Placebo 1 capsule per day for four weeks.

Interventions

Sildenafil

50 mg/day for 4 weeks

Intervention Type: DRUG

tadalafil

10 mg/day for 4 weeks.

Intervention Type: DRUG

Placebo

Placebo 1 capsule per day for four weeks.

Intervention Type: DRUG

Other Intervention Names

Viagra; Revatio; Cialis; Adcirca

Eligibility Criteria

Inclusion Criteria

1. Age 50-60 years of age

2. Ability to sign consent form (score>23 on the 30-item Mini Mental Status examination, MMSE)

3. Stable body weight for at least three months.

Exclusion Criteria

1. Physical dependence or frailty (impairment in any of the Activities of Daily Living (ADL), history of falls (>2/year) or significant weight loss in the past year).

2. Pregnancy

3. Significant heart, liver, kidney, blood or respiratory disease.

4. Peripheral vascular disease.

5. Diabetes mellitus or other untreated endocrine disease.

6. Active cancer

7. Use of nitrates.

8. Recent (within 6 months) treatment with anabolic steroids, or corticosteroids.

9. Alcohol or drug abuse.

10. Severe depression (>5 on the 15-item Geriatric Depression Scale, GDS).

11. Cardiac abnormalities such as cardiac shunt or previously diagnosed pulmonary hypertension.

12. Systolic blood pressure <100 or>150, diastolic blood pressure <60 or 90>. This range is smaller than the acceptable range stated in the prescribing information for sildenafil/tadalafil (90/50 and <170/110).

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

The University of Texas Medical Branch, Galveston

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Melinda Sheffield-Moore, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Texas Medical Branch, Galveston

Locations

University of Texas Medical Branch

Galveston, Texas, United States

Countries

United States

Other Identifiers

12-153

Identifier Type: -

Identifier Source: org_study_id